GLP-1glp-1mashmeta-analysisliver disease

PROSPERO registration sets GLP-1 meta-analysis on MASH histology

The planned review will pool randomized trials of GLP-1 receptor agonists versus placebo, with MASH resolution and fibrosis reduction as the primary endpoint.

By Maren Holt · Senior Reporter, GLP-1

Sep 27 20:00 ETSource: Frontiers in medicine

The wire

01Registered as PROSPERO CRD420261287573, the protocol covers PubMed, Embase, Cochrane Library and Web of Science searches, random-effects pooling and trial sequential analysis.
02MASH has no approved pharmacotherapy in the authors' framing, so a synthesis of histological endpoints bears on how incretins get positioned in liver disease.
03This is a protocol only; no results are reported and the pooled evidence base has not yet been assembled.

From the source

GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials
Frontiers in medicine · 2026 · Sun SP, Fang Y, Liu L et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42865473/